The aim of the study was to evaluate the disposition of plasma unbound cefazolin in patients undergoing cardiothoracic surgery with cardiopulmonary bypass (CPB).
| INTRODUCTION
Surgical site infection (SSI) is one of the major postoperative complications and is associated with increased morbidity and mortality. 1, 2 Particularly, SSIs (such as mediastinitis) that develop in patients undergoing cardiothoracic surgery are associated with a high mortality. Previous meta-analyses revealed that antimicrobial prophylaxis used in cardiothoracic surgery is associated with better surgical outcomes. 3, 4 While cardiothoracic surgery is often performed with cardiopulmonary bypass (CPB), there is a paucity of knowledge about changes that may occur in the pharmacokinetics of drugs during CPB. As a result, consensus has not been attained about the choice and dosing protocols of antibiotics for these patients. 5 The guidelines of the American Society of Health-System Pharmacists recommend that traditional antimicrobial prophylaxis protocols for general surgery should not be changed for patients undergoing cardiothoracic surgery with CPB, unless further clinical outcome data obtained from well-designed studies are available. 1 Nevertheless, recent studies argued that conventional regimens of cefazolin prophylaxis for these patients may not be reliable in maintaining a target plasma threshold (for example, total drug concentration of 40 μg mL −1 , assuming normal protein binding of 80%-86% 6, 7 during CPB) at intraoperative trough and/or at wound closure in patients with normal renal function undergoing cardiac surgery with CPB. ) occurs, and it may increase the volume of distribution and alter plasma protein binding of drugs that have a small volume of distribution and extensive plasma protein binding. In addition, heparin is routinely administered intravenously at 300 to 400 U kg −1 into the CPB circuit for anticoagulation. A heparin-induced increase in plasma free fatty acids may competitively displace drugs from their albumin-binding sites. 8 Furthermore, CPB may affect systemic elimination of drugs by altering hepatic and/or renal blood flow. 9, 10 Current guidelines recommend intravenous cefazolin sodium as the drug of choice for antimicrobial prophylaxis in patients undergoing surgery, due to its excellent activity against common pathogens causing SSI. 1, 11 Since cefazolin binds extensively to albumin (80%-86%) 6, 7 and has a small volume of distribution (10 L per body), 6 its disposition may be particularly susceptible to CPB-induced physiological changes. Indeed, previous studies reported a 28%-50% decrease in plasma total cefazolin concentration during CPB. 12, 13 Collectively, there is a paucity of knowledge about the impact of CPB on the disposition of cefazolin. Here, we report the disposition of total and unbound cefazolin throughout cardiothoracic surgery performed with CPB, with reference to the target plasma unbound drug concentration. 
| MATERIALS AND METHODS

| Patients and CPB procedures
| Antimicrobial prophylaxis
Cefazolin sodium for injection (Nichiiko, Toyama, Japan) at a dose of 1 g was infused intravenously over 30 minutes. The infusion was started approximately 60 minutes before skin incision. Thereafter, additional dose was administered every 4 hours. In addition, 2 g of cefazolin was added to the priming solution of the CPB circuit. (Figure 1 ).
| Blood Samplings
Blood samples were collected before the preoperative dose was . Tetrahydrolipstatin was added to blood samples for preventing in vitro lipolysis of triglyceride by heparin after sample collection. 15, 16 Strictly speaking, serum was separated from blood samples taken before and during surgery until CPB was commenced, but plasma was separated from those taken during CPB and thereafter when patients' blood was anticoagulated by heparin in vivo. For avoiding unnecessary complexity, we describe blood samples obtained by centrifugation of tubes as plasma hereafter. This is because our major interests were to study the disposition of cefazolin during and after CPB. Blood samples were centrifuged at 3000g for 10 minutes, and the separated plasma samples were kept in ice water bath until protein binding study. Plasma albumin concentrations were determined by the bromocresol green method using the A/G B-test kit (Wako Pure Chemical Industries, Ltd., Osaka, Japan) according to the manufacturer's instructions.
| Plasma cefazolin analysis
Total and unbound cefazolin concentrations in plasma were analyzed using a high performance liquid chromatography (HPLC) with UV detection method according to that reported by Nygard G. et al. . Intra-and interday coefficients of variation of cefazolin assay were less than 5.8% and 6.5%, respectively.
| Target plasma cefazolin concentrations
We set plasma unbound cefazolin concentrations of 2 and 8 μg . In a patient whose course of surgery was complicated before CPB initiation, the second dose of cefazolin was administered before the initiation of CPB ASADA ET AL.
where C b and C u are protein-bound and unbound drug concentrations, respectively, at equilibrium; and C prot is the concentration of binding protein. Since plasma protein binding of cefazolin has been shown to be attributed exclusively to albumin, 19 C prot may be replaced by plasma albumin concentration (C alb ). Rearranging Equation 1 yields the following equation:
where C tot is total drug concentrations. Note that the dissociation constant (K D ) equals 1/Ka by definition. We assume that CPB alters plasma albumin concentration but not the binding affinity of albumin to cefazolin. We also assume that the equilibrium of drug-protein binding is attained rapidly. Solving Equation 2 for Cu, the following equation is obtained 19 :
By substituting C tot , C alb , and K D into Equation 3, we estimated
Cu for each plasma sample. Here, C tot and C alb were measured in the plasma samples collected from patients during surgery, and K a was obtained from the literature. 19 Then, we compared plasma unbound cefazolin concentrations (Cu) that were estimated by Equation 3 and those actually measured.
| Statistical analyses
Demographic variables of the participants are presented as mean ± SD with range. Data of unbound fraction of cefazolin and plasma albumin concentration are presented using box and whisker plots.
Nonparametric multiple comparisons of plasma unbound fraction of cefazolin and plasma albumin concentration before skin incision, during CPB, and at the end of CPB were performed using the SteelDwass' test for pair-wise comparisons. Correlation between observed unbound cefazolin concentration and estimated concentration was analyzed by the least-squares linear regression. A P value less than 0.001 was considered statistically significant.
| RESULTS
| Patient characteristics and adverse drug reactions
Twenty-seven patients (18 males and nine females, aged 44-93 years) were enrolled in the study and all subjects completed the study ( . Nevertheless, 99% of total plasma cefazolin concentrations measured during surgery exceeded this value in our study.
Plasma unbound fractions of cefazolin and albumin concentrations obtained before skin incision, during CPB, and at the end of CPB are shown in Figure 3 . The median plasma unbound fraction of T A B L E 1 Demographic, laboratory and relevant cardiopulmonary bypass (CPB) parameters of patients
Characteristics Data
Gender (male/female) 18/9 cefazolin measured before skin incision was 21%, but increased during CPB to 45%, and thereafter showed a tendency of returning to the basal level at wound closure (25%) (Figure 3 ). Significant (P < 0.001) differences were observed between before skin incision and during CPB, and between during CPB and at wound closure. In addition, the median plasma albumin concentration before skin incision was 36 g L −1
, but decreased significantly (P < 0.001) during CPB to 27 g L −1
, and increased again to 34 g L −1 at wound closure. Significant (P < 0.001) differences were observed between before skin incision and during CPB, and between during CPB and at wound closure ( Figure 3 ).
| Comparison between estimated and measured plasma unbound cefazolin concentrations
A total of 199 pairs of data set were available for this analysis. A significant (P < 0.001) linear correlation with a slope close to unity was observed between the estimated plasma unbound cefazolin concentrations (C u,obs ) and the actually measured concentrations (C u,measured ): C u,obs = 1.05・C u,measured + 1.49 (r = 0.86).
| DISCUSSION
In the present study, we found that the median plasma unbound fraction of cefazolin showed an abrupt and profound increase during CPB (45%) compared to that at preoperative period (21%) (Figure 2) . We speculate that these changes may be attributable to dilutional reduction of plasma albumin levels and saturable plasma protein binding of cefazolin. 20 Especially, the CPB circuit was primed with approximately 1.3 L of crystalloid solution, and fresh frozen plasma was subsequently administered to compensate blood loss during operation (Table 1) ) and unbound (8 μg mL , respectively. After receiving the first dose of cefazolin (1 g) before skin incision, initiation of CPB was delayed until 366 min from the first dose due to difficulties in operation, and he received the second dose of cefazolin before the initiation of CPB. The total and unbound plasma trough concentrations obtained immediately before the second dose (at 270 min from the first dose) were 40.4 and 6.0 μg mL −1 , respectively. Total and unbound plasma drug concentrations measured at the initiation of CPB were higher than the respective target concentrations. circuit. Our speculation may be supported by our finding of a good agreement between the unbound drug concentrations in plasma estimated using the Langmuir model and the concentrations actually measured. We estimated unbound cefazolin concentrations assuming that CPB affects the maximum binding capacity (i.e, plasma albumin concentration) but not the binding affinity of cefazolin binding. Nevertheless, we cannot completely exclude the possibility that heparininduced elevation of plasma free fatty acids is associated with the increased unbound fraction of cefazolin. Heparin is routinely used for anticoagulation during CPB, and it increases the activity of lipoprotein lipase in tissues and plasma, thereby increasing nonesterified (free) fatty acids concentrations. Fujiwara and Amisaki 21 demonstrated that free fatty acids compete with drug binding at the warfarin-binding site of human albumin. Cefazolin has been shown to bind to this site. 22 While we added tetrahydrolipstatin during blood sampling to prevent in vitro lipolysis after blood sample collection, further studies are necessary to clarify the contribution of free fatty acids to altered plasma protein binding of cefazolin.
There has been an extensive debate over the target plasma unbound concentrations of cefazolin for the prevention of SSI.
While 2 μg mL −1 may be enough against the most prevalent pathogen of methicillin-sensitive Staphylococcus aureus (MSSA) and 4 μg mL −1 may be enough against a sensitive Enterobacteriaceae, 8 μg
may be required for a resistant Enterobacteriaceae. 1, 7 Holllis et al. adopted an inhibitory threshold of 16 μg mL −1 of unbound cefazolin for the validation of a dosing strategy for surgery requiring cardiopulmonary bypass. 23 Recently, Zelenitsky et al reported that cefazolin plasma concentration during wound closure was associated with SSI at 30 days and that total cefazolin closure concentration of 104 μg mL −1 was a significant threshold for an increased risk of infection. 24 In this context, we assessed the performance of our institutional regimen of cefazolin in reference to plasma unbound cefazolin concentrations of 2 and 8 μg mL with CPB was the same as that of healthy subjects (80%-86%). 6, 7 Our study suggests that they might have underestimated the The present study has some limitations. Due to the small number of participants (n = 27) and lack of a comparator group receiving a conventional regimen, we cannot compare the probability of target attainment and the efficacy of antimicrobial prophylaxis between our protocol and the conventional regimen. In addition, we were unable to perform conventional pharmacokinetic analysis of total and unbound plasma cefazolin concentrations, since only a limited number of samples (n = 7 to 10) were available from each patient. We are examining the possibility of using our datasets to perform a population pharmacokinetic analysis, as mentioned above. For the prevention of SSI, it is important to determine the target site drug concentrations. Douglas et al measured the subcutaneous interstitial fluid (ISF) concentrations of cefazolin in patients undergoing elective/semielective abdominal aortic aneurysm open repair surgery and reported that the penetration of unbound drug from plasma to ISF was 85% (78% to 106%). 28 Thus, the plasma concentration of unbound cefazolin would reflect the drug concentration at the target site.
In conclusion, our results indicate that altered plasma protein binding of the drug during and after CPB should be taken into consideration when modeling the disposition of unbound drug concentrations. Individualization of antimicrobial prophylaxis with cefazolin for adult patients undergoing CPB may be performed using a comprehensive pharmacokinetic modeling taking into account CPBinduced physiological changes.
ACKNOWLEDG EMENTS
The study was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number JP17H00452. The authors appreciate the staff of operation room for their assistance in the study.
DISCLOSURE
The authors have stated explicitly that there are no conflicts of interest in connection with this article.
O R C I D
Masashi Nagata http://orcid.org/0000-0003-3169-7210
